Form 4: Cardlytics Director Acquires Shares

John L. Klinck Jr., a Director at Cardlytics, Inc., acquired 11,000 shares of common stock through the vesting of restricted stock units.

Summary

• John L. Klinck Jr., a Director at Cardlytics, Inc. (CDLX), reported a transaction on May 20, 2026.
• He acquired 11,000 shares of common stock.
• This acquisition was a result of the vesting of restricted stock units (RSUs).
• The RSUs vested in full on the one-year anniversary of their grant date, provided he remained a director.
• Following this transaction, Klinck beneficially owns 89,593 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard insider transaction (vesting of RSUs) without indicating new buying or selling activity that would signal a strong positive or negative sentiment.

Positives

• Director John L. Klinck Jr. acquired 11,000 shares of Cardlytics common stock.
• The acquisition was through the vesting of restricted stock units, indicating continued service and commitment.
• The shares vested in full, suggesting the conditions for vesting were met.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it solely reports a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that Form 4 filings, like this one from Cardlytics, are standard disclosures for insider transactions. They provide transparency into the holdings and activities of company directors and officers, which is a key aspect of corporate governance and investor relations in the financial technology sector.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased transparency into director's beneficial ownership, reinforcing governance standards.
• Management: Demonstrates continued commitment and alignment with company performance through equity vesting.

Key Dates

Keywords

Cardlytics, CDLX, Form 4, Insider Transaction, Restricted Stock Units, Director, Common Stock, Beneficial Ownership